{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000128","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-09-30T20:20:20+00:00","discovered_at":"2026-09-30T20:21:00.259580+00:00","generated_at":"2026-10-12T14:06:07.349967+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Halozyme elects James Daly to board, term runs through 2029 annual meeting","bullets":["James Daly was elected to Halozyme Therapeutics' Board of Directors on September 28, 2026.","Daly's director term ends at the company's annual meeting of stockholders in 2029; he was not assigned to any board committee.","Daly will receive compensation under Halozyme's non-employee director program, including cash retainers and restricted stock and stock option awards.","Halozyme said there are no arrangements or understandings for Daly's election and no related person transactions between him and the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000128","json":"https://secwatch.observer/filing/0001159036-26-000128.json","markdown":"https://secwatch.observer/filing/0001159036-26-000128.md","text":"https://secwatch.observer/filing/0001159036-26-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000128/0001159036-26-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000128/halo-20260928.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:06:07.349967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}